Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovaBridge BiosciencesNBP · Entity 6324 | EVP, Clinical Development | August 30, 2026 | September 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovaBridge Biosciences
Report date August 30, 2026 · Filed September 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 307,483 |
Reported balance
After 2026-08-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-30 · Exercise / conversion · Acquired 9,382 · Balance 307,483 F1: The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. F2: Reported securities are represented by 4,079 ADSs. F3: Each restricted stock unit ("RSU") represents a contingent right to receive one ADS. F4: Reported securities are represented by 133,688 ADSs. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 304,201 |
Reported balance
After 2026-08-31 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-08-31 · Sale · Disposed 3,282 · Balance 304,201 F1: The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. F5: Reported securities are represented by 1,427 ADSs. F6: Reported sales price represents the converted sales price of the ADSs of $1.8186. F7: Reported securities are represented by 132,261 ADSs. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 28,558 |
Reported balance
After 2026-08-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-30 · Exercise / conversion · Disposed 4,079 · Balance 28,558 F3: Each restricted stock unit ("RSU") represents a contingent right to receive one ADS. F8: Reported securities represent ADSs. F9: On May 30, 2024, the Reporting Person was granted 65,270 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 30th day of each third month. F1: The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.
F2: Reported securities are represented by 4,079 ADSs.
F3: Each restricted stock unit ("RSU") represents a contingent right to receive one ADS.
F4: Reported securities are represented by 133,688 ADSs.
F5: Reported securities are represented by 1,427 ADSs.
F6: Reported sales price represents the converted sales price of the ADSs of $1.8186.
F7: Reported securities are represented by 132,261 ADSs.
F8: Reported securities represent ADSs.
F9: On May 30, 2024, the Reporting Person was granted 65,270 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 30th day of each third month.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2026 Filed Sep 1, 2026 22:00 UTC | NovaBridge Biosciences NBP · Entity 6324 | SaleOrdinary Shares | 3,282 | $0.79 | $2,592.78 |
DisclosureSEC source: 0002114309-26-000007 · form4-09012026_060901.xml · nonDerivative · entry 2 Xu Cong Claire · CIK 0002114309 · EVP, Clinical Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 304,201 F1 · security: The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. F5 · shares: Reported securities are represented by 1,427 ADSs. F6 · price: Reported sales price represents the converted sales price of the ADSs of $1.8186. F7 · balance_after: Reported securities are represented by 132,261 ADSs. Read SEC document |
| August 30, 2026 Filed Sep 1, 2026 22:00 UTC | NovaBridge Biosciences NBP · Entity 6324 | Exercise / conversionRestricted Share Units · Derivative | 4,079 | $0.00 | $0.00 |
DisclosureSEC source: 0002114309-26-000007 · form4-09012026_060901.xml · derivative · entry 3 Xu Cong Claire · CIK 0002114309 · EVP, Clinical Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,558 Underlying: Ordinary Shares · 4,079 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ADS. F8 · shares: Reported securities represent ADSs. F9 · derivative.exercise_date: On May 30, 2024, the Reporting Person was granted 65,270 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 30th day of each third month. F9 · derivative.expiration_date: On May 30, 2024, the Reporting Person was granted 65,270 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 30th day of each third month. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. F8 · derivative.underlying_shares: Reported securities represent ADSs. Read SEC document |
| August 30, 2026 Filed Sep 1, 2026 22:00 UTC | NovaBridge Biosciences NBP · Entity 6324 | Exercise / conversionOrdinary Shares | 9,382 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002114309-26-000007 · form4-09012026_060901.xml · nonDerivative · entry 1 Xu Cong Claire · CIK 0002114309 · EVP, Clinical Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 307,483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. F2 · shares: Reported securities are represented by 4,079 ADSs. F3 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ADS. F4 · balance_after: Reported securities are represented by 133,688 ADSs. Read SEC document |
| July 06, 2026 Filed Jul 7, 2026 23:50 UTC | NovaBridge Biosciences NBP · Entity 6324 | SaleOrdinary Shares | 4,485 | $0.89 | $3,991.65 |
DisclosureSEC source: 0002114309-26-000005 · form4-07072026_110715.xml · nonDerivative · entry 2 Xu Cong Claire · CIK 0002114309 · SVP, Clinical Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 298,101 F1 · security: The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. F5 · shares: Reported securities are represented by 1,950 ADSs. F6 · price: Reported sales price represents the converted sales price of the ADSs of $2.04. F7 · balance_after: Reported securities are represented by 129,609 ADSs. Read SEC document |
| July 04, 2026 Filed Jul 7, 2026 23:50 UTC | NovaBridge Biosciences NBP · Entity 6324 | Exercise / conversionRestricted Share Units · Derivative | 5,405 | $0.00 | $0.00 |
DisclosureSEC source: 0002114309-26-000005 · form4-07072026_110715.xml · derivative · entry 3 Xu Cong Claire · CIK 0002114309 · SVP, Clinical Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,405 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ADS. F8 · shares: Reported securities represent ADSs. F9 · derivative.exercise_date: Fully vested. F9 · derivative.expiration_date: Fully vested. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. F8 · derivative.underlying_shares: Reported securities represent ADSs. F8 · balance_after: Reported securities represent ADSs. Read SEC document |
| July 04, 2026 Filed Jul 7, 2026 23:50 UTC | NovaBridge Biosciences NBP · Entity 6324 | Exercise / conversionOrdinary Shares | 12,432 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002114309-26-000005 · form4-07072026_110715.xml · nonDerivative · entry 1 Xu Cong Claire · CIK 0002114309 · SVP, Clinical Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 302,586 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. F2 · shares: Reported securities are represented by 5,405 ADSs. F3 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ADS. F4 · balance_after: Reported securities are represented by 131,559 ADSs. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 22:46 UTC | NovaBridge Biosciences NBP · Entity 6324 | SaleOrdinary Shares | 3,494 | $3.94 | $13,766.36 |
DisclosureSEC source: 0002114309-26-000003 · form4-06022026_100655.xml · nonDerivative · entry 2 Xu Cong Claire · CIK 0002114309 · SVP, Clinical Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 290,154 F1 · security: The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. F5 · shares: Reported securities are represented by 1,519 ADSs. F6 · price: Reported sales price represents the converted sales price of the ADSs of $1.71. F7 · balance_after: Reported securities are represented by 126,154 ADSs. Read SEC document |
| May 30, 2026 Filed Jun 2, 2026 22:46 UTC | NovaBridge Biosciences NBP · Entity 6324 | Exercise / conversionRestricted Share Units · Derivative | 4,079 | $0.00 | $0.00 |
DisclosureSEC source: 0002114309-26-000003 · form4-06022026_100655.xml · derivative · entry 3 Xu Cong Claire · CIK 0002114309 · SVP, Clinical Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,637 Underlying: Ordinary Shares · 4,079 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ADS. F8 · shares: Reported securities represent ADSs. F9 · derivative.exercise_date: On May 30, 2024, the Reporting Person was granted 65,270 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 30th day of each third month. F9 · derivative.expiration_date: On May 30, 2024, the Reporting Person was granted 65,270 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 30th day of each third month. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. F8 · derivative.underlying_shares: Reported securities represent ADSs. F8 · balance_after: Reported securities represent ADSs. Read SEC document |
| May 30, 2026 Filed Jun 2, 2026 22:46 UTC | NovaBridge Biosciences NBP · Entity 6324 | Exercise / conversionOrdinary Shares | 9,382 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002114309-26-000003 · form4-06022026_100655.xml · nonDerivative · entry 1 Xu Cong Claire · CIK 0002114309 · SVP, Clinical Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 293,648 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. F2 · shares: Reported securities are represented by 4,079 ADSs. F3 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ADS. F4 · balance_after: Reported securities are represented by 127,673 ADSs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.